Boehringer Ingelheim: Obesity trials
The registry lists 32 Obesity studies with Boehringer Ingelheim as lead sponsor. 5 are open to participants now and 4 have results posted.
Phase 1 17Phase 2 4Phase 3 10No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Compare How Survodutide is Taken up by the Body When Given in 2 Formulations to People With Overweight or ObesityNot yet recruitingNCT07940244Phase 1
- SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose WeightRecruitingNCT07855900Phase 3
- ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver DiseaseNot yet recruitingNCT07850063Phase 3
- SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose WeightRecruitingNCT07850050Phase 3
- A Study to Test How Well Different and Multiple Doses of BI 3034701 Are Tolerated in People Living With Overweight or ObesityRecruitingNCT07754474Phase 1
- A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver DiseaseCompletedNCT05970640Phase 1Results posted
- A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose WeightCompletedNCT04667377Phase 2Results posted
- Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN StudyCompletedNCT02632747Phase 2Results posted
- Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes MellitusCompletedNCT01306214Phase 3Results posted
- A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or ObesityActive, not recruitingNCT07768813Phase 1
- A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Japanese Healthy People and Japanese People With Obesity or OverweightActive, not recruitingNCT07693231Phase 1
- A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or OverweightActive, not recruitingNCT07662122Phase 2
- A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like InjectorCompletedNCT07413913Phase 1
- A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the BodyActive, not recruitingNCT07407348Phase 1
- A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With ObesityActive, not recruitingNCT06745284Phase 1
- A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or ObesityCompletedNCT06564441Phase 1
- A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the BodyCompletedNCT06492135Phase 1
- A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain ActivityCompletedNCT06352424Phase 1
- A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)CompletedNCT06309992Phase 3
- A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose WeightCompletedNCT06214741Phase 3
- A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or ObesityCompletedNCT06200467Phase 1
- A Study to Test Whether Survodutide Helps Japanese People Living With Obesity DiseaseCompletedNCT06176365Phase 3
- A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)CompletedNCT06077864Phase 3
- A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose WeightCompletedNCT06066528Phase 3
- A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose WeightCompletedNCT06066515Phase 3
- A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906CompletedNCT05751226Phase 1
- A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906CompletedNCT05296733Phase 1
- A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the LiverActive, not recruitingNCT05202353Phase 1
- A Study to Test How Well Different Doses of BI 1356225 Are Tolerated by Men and Women With Obesity or OverweightCompletedNCT04447261Phase 1
- A Study to Test Different Doses of BI 456906 in Patients With ObesityCompletedNCT03591718Phase 1
- Observational Non-interventional Study (Anwendungsbeobachtung) With Telmisartan in High-risk HypertensivesCompletedNCT00539487
- The Primary Objective of This Study is to Determine Whether MICARDIS® Improves Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive SubjectsCompletedNCT00146289Phase 2